Vascular calcification and renal bone disorders

Scientific World Journal

Volumn 2014, Issue , 2014, Pages

  Lu, Kuo Cheng ^a   Wu, Chia Chao ^b   Yen, Jen Fen ^c   Liu, Wen Chih ^c  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c CARDINAL TIEN HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIPROTEIN; CALCIUM; CALCIUM BINDING PROTEIN; DENOSUMAB; FETUIN A; INDICAN; MAGNESIUM; MATRIX GLUTAMATE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE[1-34]; PEPTIDES AND PROTEINS; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PYROPHOSPHATE; REACTIVE OXYGEN METABOLITE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SODIUM THIOSULFATE; UNCLASSIFIED DRUG; VITAMIN; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN K GROUP;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; APOPTOSIS; ARTERIOSCLEROSIS; ARTERY CALCIFICATION; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BONE DEVELOPMENT; BONE METABOLISM; BONE TURNOVER; CALCIFICATION; CALCIUM HOMEOSTASIS; CARDIAC VALVE CALCIFICATION; CHONDROGENESIS; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; INFLAMMATION; METABOLIC BONE DISEASE; MOLECULAR PATHOLOGY; NONHUMAN; PATHOLOGICAL ANATOMY; PHOSPHATE METABOLISM; PROTEIN DEGRADATION; PROTEIN MODIFICATION; RENAL OSTEODYSTROPHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VALVULAR HEART DISEASE; ZINC DEFICIENCY; ANIMAL; CHRONIC KIDNEY FAILURE; COMPLICATION; METABOLISM; PATHOLOGY; VASCULAR CALCIFICATION;

ANIMALS; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; VASCULAR CALCIFICATION;

EID: 84926162523     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/637065     Document Type: Review

References (218)

1. P. J. Matias, C. Ferreira, C. Jorge et al. , "25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients, " Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 611-618, 2009.
2. M. Naves-Díaz, D. Álvarez-Hernández, J. Passlick-Deetjen et al. , "Oral active vitamin D is associated with improved survival in hemodialysis patients, " Kidney International, vol. 74, no. 8, pp. 1070-1078, 2008.
3. G. M. London, S. J. Marchais, A. P. Guérin, P. Boutouyrie, F. Métivier, and M. De Vernejoul, "Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD, " Journal of the American Society of Nephrology, vol. 19, no. 9, pp. 1827-1835, 2008.
4. M. Rodríguez-García, C. Gómez-Alonso, M. Naves-Díaz et al. , "Vascular calcifications, vertebral fractures and mortality in haemodialysis patients, " Nephrology Dialysis Transplantation, vol. 24, no. 1, pp. 239-246, 2009.
5. D. Goldsmith, E. Ritz, and A. Covic, "Vascular calcification: a stiff challenge for the nephrologist-does preventing bone disease cause arterial disease?" Kidney International, vol. 66, no. 4, pp. 1315-1333, 2004.
6. M. Wu, C. Rementer, and C. M. Giachelli, "Vascular calcification: an update on mechanisms and challenges in treatment, " Calcified Tissue International, vol. 93, no. 4, pp. 365-373, 2013.
7. W. E. Moody, N. C. Edwards, C. D. Chue, C. J. Ferro, and J. N. Townend, "Arterial disease in chronic kidney disease, " Heart, vol. 99, no. 6, pp. 365-372, 2013.
8. "K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, " The American Journal of Kidney Diseases, vol. 39, no. 2, supplement 1, pp. S1-S266, 2002.
9. G. Eknoyan, N. Lameire, R. Barsoum et al. , "The burden of kidney disease: improving global outcomes, " Kidney International, vol. 66, no. 4, pp. 1310-1314, 2004.
10. M. Mafham, J. Emberson, M. J. Landray, C. Wen, and C. Baigent, "Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis, " PLoS ONE, vol. 6, no. 10, Article IDe25920, 2011.
11. J. Kjekshus, E. Apetrei, V. Barrios et al. , "Rosuvastatin in older patients with systolic heart failure, "The New England Journal of Medicine, vol. 357, no. 22, pp. 2248-2261, 2007.
12. C. M. Shanahan, M. H. Crouthamel, A. Kapustin, and C. M. Giachelli, "Arterial calcification in chronic kidney disease: key roles for calcium and phosphate, " Circulation Research, vol. 109, no. 6, pp. 697-711, 2011.
13. M. A. Frye, L. J. Melton III, S. C. Bryant et al. , "Osteoporosis and calcification of the aorta, " Bone and Mineral, vol. 19, no. 2, pp. 185-194, 1992.
14. D. P. Kiel, L. I. Kauppila, L. A. Cupples, M. T. Hannan, C. J. ODonnell, and P. W. F. Wilson, "Bone loss and the progression of abdominal aortic calcification over 25 year period: The Framingham Heart Study, " Calcified Tissue International, vol. 68, no. 5, pp. 271-276, 2001.
15. M. T. Vogt, R. SanValentin, K. Y.-. Forrest, M. C. Nevitt, and J. A. Cauley, "Bone mineral density and aortic calcification: the study of osteoporotic fractures, " Journal of the American Geriatrics Society, vol. 45, no. 2, pp. 140-145, 1997.
16. J. B. Cannata-Andía, M. Rodríguez-García, N. Carrillo-López, M. Naves-Díaz, and B. Díaz-López, "Vascular calcifications: pathogenesis, management, and impact on clinical outcomes, " Journal of the American Society of Nephrology, vol. 17, no. 3, pp. S267-S273, 2006.
17. M. Rodríguez García, M. Navez Díaz, and J. B. Cannata Andía, "Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence, " Journal of Nephrology, vol. 18, no. 4, pp. 458-463, 2005.
18. J. B. Cannata-Andia, P. Roman-Garcia, and K. Hruska, "The connections between vascular calcification and bone health, " Nephrology Dialysis Transplantation, vol. 26, no. 11, pp. 3429-3436, 2011.
19. W. L. Lau and J. H. Ix, "Clinical detection, risk factors, and cardiovascular consequences of medial arterial calcification: a pattern of vascular injury associated with aberrant mineral metabolism, " Seminars in Nephrology, vol. 33, no. 2, pp. 93-105, 2013.
20. G. M. London, S. J. Marchais, A. P. Guerin, F. Metivier, and H. Adda, "Arterial structure and function in end-stage renal disease, " Nephrology Dialysis Transplantation, vol. 17, no. 10, pp. 1713-1724, 2002.
21. R. G. Micheletti, G. A. Fishbein, J. S. Currier, and M. C. Fishbein, "Mönckeberg sclerosis revisited: a clarification of the histologic definition of Mönckeberg sclerosis, " Archives of Pathology and Laboratory Medicine, vol. 132, no. 1, pp. 43-47, 2008.
22. A. Lindbom, "Arteriosclerosis and arterial thrombosis in the lower limb; a roentgenological study, " Acta Radiologica, Supplementum, vol. 80, pp. 1-80, 1950.
23. J. Butany, M. J. Collins, D. E. Demellawy et al. , "Morphological and clinical findings in 247 surgically excised native aortic valves, " The Canadian Journal of Cardiology, vol. 21, no. 9, pp. 747-755, 2005.
24. C. M. Otto, J. Kuusisto, D. D. Reichenbach, A. M. Gown, and K. D. OBrien, "Characterization of the early lesion of "degenerative" valvular aortic stenosis: histological and immunohistochemical studies, " Circulation, vol. 90, no. 2, pp. 844-853, 1994.
25. L. Wallby, B. Janerot-Sjöberg, T. Steffensen, and M. Broqvist, "T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves, " Heart, vol. 88, no. 4, pp. 348-351, 2002.
26. N. M. Rajamannan, M. Subramaniam, D. Rickard et al. , "Human aortic valve calcification is associated with an osteoblast phenotype, " Circulation, vol. 107, no. 17, pp. 2181-2184, 2003.
27. E. R. Mohler III, M. K. Chawla, A. W. Chang et al. , "Identification and characterization of calcifying valve cells from human and canine aortic valves, " Journal of Heart Valve Disease, vol. 8, no. 3, pp. 254-260, 1999.
28. E. R. Mohler III, F. Gannon, C. Reynolds, R. Zimmerman, M. G. Keane, and F. S. Kaplan, "Bone formation and inflammation in cardiac valves, " Circulation, vol. 103, no. 11, pp. 1522-1528, 2001.
29. J. A. Leopold, "Cellular mechanisms of aortic valve calcification, " Circulation: Cardiovascular Interventions, vol. 5, no. 4, pp. 605-614, 2012.
30. D. A. Towler, "Molecular and cellular aspects of calcific aortic valve disease, " Circulation Research, vol. 113, no. 2, pp. 198-208, 2013.
31. N. M. Rajamannan, F. J. Evans, E. Aikawa et al. , "Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research fromthe national heart and lung and blood institute aortic stenosisworking group, " Circulation, vol. 124, no. 16, pp. 1783-1791, 2011.
32. W. Karwowski, B. Naumnik, M. Szczepański, and M. Mys̈liwiec, "Themechanism of vascular calcification-a systematic review, " Medical Science Monitor, vol. 18, no. 1, pp. RA1-RA11, 2012.
33. J. H. Ix, G. M. Chertow, M. G. Shlipak, V. M. Brandenburg, M. Ketteler, and M. A. Whooley, "Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data fromthe heart and soul study, " Circulation, vol. 115, no. 19, pp. 2533-2539, 2007.
34. S. M. Ott, "Therapy for patients withCKDand lowbone mineral density, " Nature Reviews. Nephrology, vol. 9, pp. 681-692, 2013.
35. S. Mathew, K. S. Tustison, T. Sugatani, L. R. Chaudhary, L. Rifas, and K. A. Hruska, "The mechanism of phosphorus as a cardiovascular risk factor in CKD, " Journal of the American Society of Nephrology, vol. 19, no. 6, pp. 1092-1105, 2008.
36. J. L. Reynolds, A. J. Joannides, J. N. Skepper et al. , "Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calciumand phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD, " Journal of the American Society of Nephrology, vol. 15, no. 11, pp. 2857-2867, 2004.
37. M. Schoppet, R. C. Shroff, L. C. Hofbauer, and C. M. Shanahan, "Exploring the biology of vascular calcification in chronic kidney disease: whats circulating?" Kidney International, vol. 73, no. 4, pp. 384-390, 2008.
38. K. A. Hruska, S. Mathew, R. Lund, P. Qiu, and R. Pratt, "Hyperphosphatemia of chronic kidney disease, " Kidney International, vol. 74, no. 2, pp. 148-157, 2008.
39. J. Marks, E. S. Debnam, and R. J. Unwin, "Phosphate homeostasis and the renal-gastrointestinal axis, " American Journal of Physiology-Renal Physiology, vol. 299, no. 2, pp. F285-F296, 2010.
40. J. Gattineni, C. Bates, K. Twombley et al. , "FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1, " The American Journal of Physiology-Renal Physiology, vol. 297, no. 2, pp. F282-F291, 2009.
41. H. Segawa, S. Yamanaka, M. Ito et al. , "Internalization of renal type IIc Na-Pi cotransporter in response to a high-phosphate diet, " The American Journal of Physiology-Renal Physiology, vol. 288, no. 3, pp. F587-F596, 2005.
42. i cotransporter, " American Journal of Physiology: Renal Physiology, vol. 292, no. 1, pp. F395-F403, 2007.
43. M. C. Hu, M. Shi, J. Zhang et al. , "Klotho: A novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule, " The FASEB Journal, vol. 24, no. 9, pp. 3438-3450, 2010.
44. R. B. Rucker, "Calcium binding to elastin, " Advances in Experimental Medicine and Biology, vol. 48, pp. 185-209, 1974.
45. C. P. Figueiredo, N. M. Rajamannan, J. B. Lopes et al. , "Serum phosphate and hip bone mineral density as additional factors for high vascular calcification scores in a community-dwelling: the São Paulo Ageing &Health Study (SPAH), " Bone, vol. 52, no. 1, pp. 354-359, 2013.
46. P. Román-García, N. Carrillo-López, J. L. Fernández-Martín, M. Naves-Díaz, M. P. Ruiz-Torres, and J. B. Cannata-Andía, "High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression, " Bone, vol. 46, no. 1, pp. 121-128, 2010.
47. J. H. Ix, R. Katz, B. R. Kestenbaum et al. , "Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study), " Journal of the American College of Cardiology, vol. 60, no. 3, pp. 200-207, 2012.
48. T. Isakova, P. Wahl, G. S. Vargas et al. , "Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease, " Kidney International, vol. 79, no. 12, pp. 1370-1378, 2011.
49. F. Perwad, M. Y. Zhang, H. S. Tenenhouse, and A. A. Portale, "Fibroblast growth factor 23 impairs phosphorus and vitamin Dmetabolismin vivo and suppresses 25-hydroxyvitamin D-1β-hydroxylase expression in vitro, " American Journal of Physiology: Renal Physiology, vol. 293, no. 5, pp. F1577-F1583, 2007.
50. K. Wesseling-Perry and H. Jüppner, "The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications, " Bone, vol. 54, no. 2, pp. 222-229, 2013.
51. S. J. House, M. Potier, J. Bisaillon, H. A. Singer, and M. Trebak, "The non-excitable smooth muscle: calcium signaling and phenotypic switching during vascular disease, " Pflugers Archiv European Journal of Physiology, vol. 456, no. 5, pp. 769-785, 2008.
52. E. Sammels, J. B. Parys, L. Missiaen, H. de Smedt, and G. Bultynck, "Intracellular Ca2+ storage in health and disease: a dynamic equilibrium, " Cell Calcium, vol. 47, no. 4, pp. 297-314, 2010.
53. C. M. Shanahan, P. L. Weissberg, and J. C. Metcalfe, "Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells, " Circulation Research, vol. 73, no. 1, pp. 193-204, 1993.
54. D. Burger and A. Levin, ""Shedding" light on mechanisms of hyperphosphatemic vascular dysfunction, " Kidney International, vol. 83, no. 2, pp. 187-189, 2013.
55. S. Jono, C. E. McKee, A. Shioi et al. , "Phosphate regulation of vascular smoothmuscle cell calcification, " Circulation Research, vol. 87, no. 7, pp. E10-E17, 2000.
56. S. A. Steitz, M. Y. Speer, G. Curinga et al. , "Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers, " Circulation Research, vol. 89, pp. 1147-1154, 2001.
57. T. Wada, S. McKee, C. M. Giachelli, M. D. McKee, and S. Steitz, "Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin, " Circulation Research, vol. 84, pp. 166-178, 1999.
58. Y. Takei, H. Yamamoto, T. Sato et al. , "Stanniocalcin 2 is associated with ectopic calcification in β-klotho mutant mice and inhibits hyperphosphatemia-induced calcification in aortic vascular smoothmuscle cells, " Bone, vol. 50, no. 4, pp. 998-1005, 2012.
59. J. M. Martinez-Moreno, J. R. Munoz-Castaneda, C. Herencia et al. , "In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/β-catenin activation, " American Journal of Physiology: Renal Physiology, vol. 303, no. 8, pp. F1136-F1144, 2012.
60. L. Mikhaylova, J. Malmquist, and M. Nurminskaya, "Regulation of in vitro vascular calcification by BMP4, VEGF and Wnt3a, " Calcified Tissue International, vol. 81, no. 5, pp. 372-381, 2007.
61. N. Kamiya, T. Kobayashi, Y. Mochida et al. , "Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts, " Journal of Bone and Mineral Research, vol. 25, pp. 200-210, 2010.
62. R. C. Shroff, R. McNair, J. N. Skepper et al. , "Chronic mineral dysregulation promotes vascular smoothmuscle cell adaptation and extracellular matrix calcification, " Journal of the American Society of Nephrology, vol. 21, pp. 103-112, 2010.
63. G. Schlieper, A. Aretz, S. C. Verberckmoes et al. , "Ultrastructural analysis of vascular calcifications in uremia, " Journal of the American Society of Nephrology, vol. 21, pp. 689-696, 2010.
64. A. Heiss, T. Eckert, A. Aretz et al. , "Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calciumphosphate particles, "The Journal of Biological Chemistry, vol. 283, no. 21, pp. 14815-14825, 2008.
65. T. Hamano, I. Matsui, S. Mikami et al. , "Fetuin-mineral complex reflects extraosseous calcification stress in CKD, " Journal of the American Society of Nephrology, vol. 21, pp. 1998-2007, 2010.
66. M. M. El-Abbadi, A. S. Pai, E. M. Leaf et al. , "Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin, " Kidney International, vol. 75, pp. 1297-1307, 2009.
67. C. M. Shanahan, N. R. Cary, J. R. Salisbury, D. Proudfoot, P. L. Weissberg, and M. E. Edmonds, "Medial localization of mineralization-regulating proteins in association with Monckebergs sclerosis: evidence for smooth muscle cell-mediated vascular calcification, " Circulation, vol. 100, pp. 2168-2176, 1999.
68. A. Pai, E. M. Leaf, M. El-Abbadi, and C. M. Giachelli, "Elastin degradation and vascular smoothmuscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease, " The American Journal of Pathology, vol. 178, pp. 764-773, 2011.
69. A. Simionescu, K. Philips, and N. Vyavahare, "Elastin-derived peptides and TGF-beta1 induce osteogenic responses in smooth muscle cells, " Biochemical and Biophysical Research Communications, vol. 334, pp. 524-532, 2005.
70. C. H. Heldin, K. Miyazono, and P. ten Dijke, "TGF-beta signalling from cell membrane to nucleus through SMAD proteins, " Nature, vol. 390, pp. 465-471, 1997.
71. K. S. Lee, H. J. Kim, Q. L. Li et al. , "Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12, "Molecular and Cellular Biology, vol. 20, pp. 8783-8792, 2000.
72. C. M. Shanahan, N. R. Cary, J. C. Metcalfe, and P. L. Weissberg, "High expression of genes for calcification-regulating proteins in human atherosclerotic plaques, " The Journal of Clinical Investigation, vol. 93, no. 6, pp. 2393-2402, 1994.
73. H. M. Spronk, B. A. Soute, L. J. Schurgers et al. , "Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall, " Biochemical and Biophysical Research Communications, vol. 289, no. 2, pp. 485-490, 2001.
74. K. A. Lomashvili, X. Wang, R. Wallin, and W. C. ONeill, "MatrixGla proteinmetabolismin vascular smoothmuscle and role in uremic vascular calcification, " The Journal of Biological Chemistry, vol. 286, no. 33, pp. 28715-28722, 2011.
75. M. Murshed, T. Schinke, G. McKee, M. D. McKee, and G. Karsenty, "Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins, " The Journal of Cell Biology, vol. 165, pp. 625-630, 2004.
76. O. Leonard, J. Spaak, and D. Goldsmith, "Regression of vascular calcification in chronic kidney disease-feasible or fantasy? A review of the clinical evidence, " British Journal of Clinical Pharmacology, vol. 76, no. 4, pp. 560-572, 2013.
77. G. Luo, P. Ducy, M. D. McKee et al. , "Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein, " Nature, vol. 386, no. 6620, pp. 78-81, 1997.
78. T. Schinke, C. Amendt, A. Trindl, O. Poschke, W. Muller-Esterl, and W. Jahnen-Dechent, "The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. Apossible role in mineralization and calcium homeostasis, "The Journal of Biological Chemistry, vol. 271, pp. 20789-20796, 1996.
79. A. Heiss, A. DuChesne, B. Denecke et al. , "Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles, " The Journal of Biological Chemistry, vol. 278, pp. 13333-13341, 2003.
80. J. L. Reynolds, J. N. Skepper, R. McNair et al. , "Multifunctional roles for serumprotein fetuin-a in inhibition of human vascular smooth muscle cell calcification, " Journal of the American Society of Nephrology, vol. 16, pp. 2920-2930, 2005.
81. S. M. Moe, M. Reslerova, M. Ketteler et al. , "Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD), " Kidney International, vol. 67, pp. 2295-2304, 2005.
82. M. Ketteler, P. Bongartz, R. Westenfeld et al. , "Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A Cross-Sectional Study, " The Lancet, vol. 361, pp. 827-833, 2003.
83. M. Odamaki, T. Shibata, T. Takita, and H. Kumagai, "Serum fetuin-A and aortic calcification in hemodialysis patients, " Kidney International, vol. 68, no. 6, p. 2916, 2005.
84. P. Stenvinkel, K. Wang, A. R. Qureshi et al. , "Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin, " Kidney International, vol. 67, pp. 2383-2392, 2005.
85. K. A. Lomashvili, W. Khawandi, and W. C. O'Neill, "Reduced plasma pyrophosphate levels in hemodialysis patients, " Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2495-2500, 2005.
86. W. C. ONeill, M. K. Sigrist, and C. W. McIntyre, "Plasma pyrophosphate and vascular calcification in chronic kidney disease, " Nephrology, Dialysis, Transplantation, vol. 25, no. 1, pp. 187-191, 2010.
87. Y. Tintut, J. Patel, F. Parhami, and L. L. Demer, "Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway, " Circulation, vol. 102, pp. 2636-2642, 2000.
88. Z. Al-Aly, J. S. Shao, C. F. Lai et al. , "Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/-mice, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, pp. 2589-2596, 2007.
89. D. A. Towler, J. S. Shao, S. L. Cheng, J. M. Pingsterhaus, and A. P. Loewy, "Osteogenic regulation of vascular calcification, " Annals of the New York Academy of Sciences, vol. 1068, pp. 327-333, 2006.
90. P. G. Lacativa and M. L. Farias, "Osteoporosis and inflammation, " Arquivos Brasileiros de Endocrinologia e Metabologia, vol. 54, pp. 123-132, 2010.
91. C. H. Byon, A. Javed, Q. Dai et al. , "Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling, " The Journal of Biological Chemistry, vol. 283, pp. 15319-15327, 2008.
92. A. F. Zebboudj, V. Shin, and K. Bostrom, "Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells, " Journal of Cellular Biochemistry, vol. 90, no. 4, pp. 756-765, 2003.
93. S. Jono, Y. Nishizawa, A. Shioi, and H. Morii, "1, 25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormonerelated peptide, " Circulation, vol. 98, no. 13, pp. 1302-1306, 1998.
94. J. S. Shao, S. L. Cheng, N. Charlton-Kachigian, A. P. Loewy, and D. A. Towler, "Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice, " The Journal of Biological Chemistry, vol. 278, pp. 50195-50202, 2003.
95. R. Vattikuti and D. A. Towler, "Osteogenic regulation of vascular calcification: an early perspective, " American Journal of Physiology: Endocrinology and Metabolism, vol. 286, no. 5, pp. E686-E696, 2004.
96. P. A. Torres and M. De Broe, "Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease, " Kidney International, vol. 82, pp. 19-25, 2012.
97. R. C. Johnson, J. A. Leopold, and J. Loscalzo, "Vascular calcification: pathobiological mechanisms and clinical implications, " Circulation Research, vol. 99, no. 10, pp. 1044-1059, 2006.
98. G. Coen, P. Ballanti, D. Mantella et al. , "Bone turnover, osteopenia and vascular calcifications in hemodialysis patients. A histomorphometric and multislice CT study, " The American Journal of Nephrology, vol. 29, pp. 145-152, 2009.
99. F. G. Graciolli, K. R. Neves, L. M. dos Reis et al. , "Phosphorus overload and PTH induce aortic expression of Runx2 in experimental uraemia, " Nephrology, Dialysis, Transplantation, vol. 24, no. 5, pp. 1416-1421, 2009.
100. S. Salem, H. Bruck, F. H. Bahlmannet al. , "Relationshipbetween magnesium and clinical biomarkers on inhibition of vascular calcification, "TheAmerican Journal of Nephrology, vol. 35, no. 1, pp. 31-39, 2012.
101. M. Ketteler, H. Rothe, T. Krüger, P. H. Biggar, and G. Schlieper, "Mechanisms and treatment of extraosseous calcification in chronic kidney disease, " Nature Reviews Nephrology, vol. 7, no. 9, pp. 509-516, 2011.
102. T. Krueger, R. Westenfeld, M. Ketteler, L. J. Schurgers, and J. Floege, "Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification?" Kidney International, vol. 76, no. 1, pp. 18-22, 2009.
103. K. Nakagawa, Y. Hirota, N. Sawada et al. , "Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme, " Nature, vol. 468, no. 7320, pp. 117-121, 2010.
104. G. Schlieper, R. Westenfeld, T. Krüger et al. , "Circulating nonphosphorylated carboxylated matrix Gla protein predicts survival in ESRD, " Journal of the American Society of Nephrology, vol. 22, no. 2, pp. 387-395, 2011.
105. A. Alonso, F. L. Lopez, K. Matsushita et al. , "Chronic kidney disease is associated with the incidence of atrial fibrillation: the atherosclerosis risk in communities (ARIC) study, " Circulation, vol. 123, no. 25, pp. 2946-2953, 2011.
106. P. A. Price, S. A. Faus, and M. K. Williamson, "Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 18, no. 9, pp. 1400-1407, 1998.
107. T. Coates, G. S. Kirkland, R. B. Dymock et al. , "Cutaneous necrosis from calcific uremic arteriolopathy, " American Journal of Kidney Diseases, vol. 32, no. 3, pp. 384-391, 1998.
108. M. Hayashi, I. Takamatsu, Y. Kanno, T. Yoshida, T. Abe, and Y. Sato, "A case-control study of calciphylaxis in Japanese endstage renal disease patients, " Nephrology Dialysis Transplantation, vol. 27, no. 4, pp. 1580-1584, 2012.
109. Y. Meng, H. Zhang, Y. Li, Q. Li, and L. Zuo, "Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats, " Bone, vol. 58, pp. 168-176, 2014.
110. D. E. Green, "The potentials of ascorbic acid, " The Biochemical Journal, vol. 27, pp. 1044-1048, 1933.
111. R. T. Franceschi, "The role of ascorbic acid in mesenchymal differentiation, " Nutrition Reviews, vol. 50, no. 3, pp. 65-70, 1992.
112. F. M. Altaf, T. M. Hering, N. H. Kazmi, J. U. Yoo, and B. Johnstone, "Ascorbate-enhanced chondrogenesis of ATDC5 cells, " European Cells and Materials, vol. 12, pp. 64-70, 2006.
113. C. Farquharson, J. L. Berry, E. B. Mawer, E. Seawright, and C. C. Whitehead, "Ascorbic acid-induced chondrocyte terminal differentiation: the role of the extracellular matrix and 1, 25-dihydroxyvitamin D, " European Journal of Cell Biology, vol. 76, no. 2, pp. 110-118, 1998.
114. P. Ciceri, E. Volpi, I. Brenna et al. , "Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation, " Nephrology Dialysis Transplantation, vol. 27, no. 1, pp. 122-127, 2012.
115. G. D. Roodman, "Vitamin E: good for the heart, bad for the bones?" Nature Medicine, vol. 18, no. 4, pp. 491-492, 2012.
116. K. Fujita, M. Iwasaki, H. Ochi et al. , "Vitamin E decreases bone mass by stimulating osteoclast fusion, " Nature Medicine, vol. 18, no. 9, pp. 589-594, 2012.
117. Kidney Disease: Improving Global Outcomes (KDIGO) CKDMBD Work Group, "KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), " Kidney International. Supplement, vol. 113, pp. S1-S130, 2009.
118. P. A. Price, N. Omid, T. N. Than, and M. K. Williamson, "The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption, " Calcified Tissue International, vol. 71, no. 4, pp. 356-363, 2002.
119. D. Haffner, B. Hocher, D. Müller et al. , "Systemic cardiovascular disease in uremic rats induced by 1, 25(OH) 2D3, " Journal of Hypertension, vol. 23, no. 5, pp. 1067-1075, 2005.
120. M. Mizobuchi, H. Ogata, F. Koiwa, E. Kinugasa, and T. Akizawa, "Vitamin D and vascular calcification in chronic kidney disease, " Bone, vol. 45, supplement 1, pp. S26-S29, 2009.
121. M. Mizobuchi, J. L. Finch, D. R. Martin, and E. Slatopolsky, "Differential effects of vitaminDreceptor activators on vascular calcification in uremic rats, " Kidney International, vol. 72, no. 6, pp. 709-715, 2007.
122. T. Suda, F. Takahashi, and N. Takahashi, "Bone effects of vitamin D-discrepancies between in vivo and in vitro studies, " Archives of Biochemistry and Biophysics, vol. 523, no. 1, pp. 22-29, 2012.
123. K. A. Lomashvili, X. Wang, and W. C. ONeill, "Role of local versus systemic vitamin D receptors in vascular calcification, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 34, no. 1, pp. 146-151, 2014.
124. T. Inoue and H. Kawashima, "1, 25-dihydroxyvitamin D3 stimulates 45Ca2+-uptake by cultured vascular smooth muscle cells derived from rat aorta, " Biochemical and Biophysical Research Communications, vol. 152, no. 3, pp. 1388-1394, 1988.
125. S. Mathew, R. J. Lund, L. R. Chaudhary, T. Geurs, and K. A. Hruska, "Vitamin D receptor activators can protect against vascular calcification, " Journal of the American Society of Nephrology, vol. 19, no. 8, pp. 1509-1519, 2008.
126. R. Shroff, M. Egerton, M. Bridel et al. , "A bimodal association of vitamin d levels and vascular disease in children on dialysis, " Journal of the American Society of Nephrology, vol. 19, no. 6, pp. 1239-1246, 2008.
127. A. Levin and C. L. Yan, "Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?" Kidney International, vol. 68, no. 5, pp. 1973-1981, 2005.
128. C. P. Kovesdy, S. Ahmadzadeh, J. E. Anderson, and K. Kalantar-Zadeh, "Association of activated vitamin D treatment and mortality in chronic kidney disease, " Archives of Internal Medicine, vol. 168, no. 4, pp. 397-403, 2008.
129. L. D. Quarles, "A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease, " Seminars in Nephrology, vol. 33, no. 2, pp. 130-142, 2013.
130. S. Y. Wu, Y. R. Yu, Y. Cai et al. , " Endogenous aldosterone is involved in vascular calcification in rat, " Experimental Biology and Medicine (Maywood), vol. 237, no. 1, pp. 31-37, 2012.
131. I. Z. Jaffe, Y. Tintut, B. G. Newfell, L. L. Demer, and M. E. Mendelsohn, "Mineralocorticoid receptor activation promotes vascular cell calcification, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 4, pp. 799-805, 2007.
132. J. N. Cooper, P. Tepper, E. Barinas-Mitchell, G. A. Woodard, and K. Sutton-Tyrrell, "Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults, " Clinical and Experimental Hypertension, vol. 34, no. 1, pp. 63-70, 2012.
133. O. de Rita, D. G. Hackam, and J. D. Spence, "Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque, " Canadian Journal of Cardiology, vol. 28, no. 6, pp. 706-711, 2012.
134. M. A. Hillaert, E. G. Lentjes, H. Kemperman et al. , "Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease, " International Journal of Cardiology, vol. 167, no. 5, pp. 1929-1935, 2013.
135. K. Lim, T. Lu, G. Molostvov et al. , "Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23, " Circulation, vol. 125, no. 18, pp. 2243-2255, 2012.
136. D. Sanz-Rosa, E. Cediel, N. de Las Heras et al. , "Participation of aldosterone in the vascular inflammatory response of spontaneouslyhypertensive rats: roleof theNF B/I B system, " Journal of Hypertension, vol. 23, no. 6, pp. 1167-1172, 2005.
137. Z. Al-Aly, "Vascular calcification in uremia: what is new and where are we going?" Advances in Chronic Kidney Disease, vol. 15, no. 4, pp. 413-419, 2008.
138. H. Lee, K. M. Woo, H. Ryoo, and J. Baek, "Tumor necrosis factor-β increases alkaline phosphatase expression in vascular smooth muscle cells via MSX2 induction, " Biochemical and Biophysical Research Communications, vol. 391, no. 1, pp. 1087-1092, 2010.
139. Y. Sun, C. H. Byon, K. Yuan et al. , "Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification, " Circulation Research, vol. 111, no. 5, pp. 543-552, 2012.
140. K. Chen and N. Rajewsky, "The evolution of gene regulation by transcription factors and microRNAs, " Nature Reviews Genetics, vol. 8, no. 2, pp. 93-103, 2007.
141. D. P. Bartel, "MicroRNAs: target recognition and regulatory functions, " Cell, vol. 136, no. 2, pp. 215-233, 2009.
142. E. M. Small and E. N. Olson, "Pervasive roles ofmicroRNAs in cardiovascular biology, " Nature, vol. 469, no. 7330, pp. 336-342, 2011.
143. F. Taibi, V. Metzinger-Le Meuth, E. MBaya-Moutoula et al. , "Possible involvement of microRNAs in vascular damage in experimental chronic kidney disease, " Biochimica et Biophysica Acta, vol. 1842, pp. 88-98, 2014.
144. N. X. Chen, K. Kiattisunthorn, K. D. ONeill et al. , "Decreased microRNAis involved in the vascular remodeling abnormalities in chronic kidney disease (CKD), " PLoS ONE, vol. 8, no. 5, Article ID e64558, 2013.
145. Y. Iwasaki, H. Yamato, T. Nii-Kono et al. , "Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats, " Nephrology Dialysis Transplantation, vol. 21, no. 10, pp. 2768-2774, 2006.
146. F. C. Barreto, D. V. Barreto, S. Liabeuf et al. , "Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients, " Clinical Journal of the American Society of Nephrology, vol. 4, no. 10, pp. 1551-1558, 2009.
147. A. Mozar, L. Louvet, C. Godin et al. , "Indoxyl sulphate inhibits osteoclast differentiation and function, " Nephrology Dialysis Transplantation, vol. 27, no. 6, pp. 2176-2181, 2012.
148. Y. H. Kim, K. A. Kwak, H. W. Gil, H. Y. Song, and S. Y. Hong, "Indoxyl sulfate promotes apoptosis in cultured osteoblast cells, " BMC Pharmacology & Toxicology, vol. 14, p. 60, 2013.
149. T. Nii-Kono, Y. Iwasaki, M. Uchida et al. , "Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells, " Kidney International, vol. 71, no. 8, pp. 738-743, 2007.
150. Y. Iwasaki, J. J. Kazama, H. Yamato, H. Shimoda, and M. Fukagawa, "Accumulated uremic toxins attenuate bone mechanical properties in rats with chronic kidney disease, " Bone, vol. 57, pp. 477-483, 2013.
151. S. Goto, K. Kitamura, K. Kono, K. Nakai, H. Fujii, and S. Nishi, "Association between AST-120 and abdominal aortic calcification in predialysis patients with chronic kidney disease, " Clinical and Experimental Nephrology, vol. 17, no. 3, pp. 365-371, 2013.
152. K. I. Boström, N. M. Rajamannan, and D. A. Towler, "The regulation of valvular and vascular sclerosis by osteogenic morphogens, " Circulation Research, vol. 109, no. 5, pp. 564-577, 2011.
153. C. Liu, T. S. Walter, P. Huang et al. , "Structural and functional insights of RANKL-RANK interaction and signaling, " The Journal of Immunology, vol. 184, no. 12, pp. 6910-6919, 2010.
154. M. Heymann, F. Herisson, J. Davaine et al. , "Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds, " Cytokine, vol. 58, no. 2, pp. 300-306, 2012.
155. M. Steinmetz, D. Skowasch, N. Wernert et al. , "Differential profile of the OPG/RANKL/RANK-system in degenerative aortic native and bioprosthetic valves, " The Journal of Heart Valve Disease, vol. 17, no. 2, pp. 187-193, 2008.
156. B. F. Boyce and L. Xing, "Biology of RANK, RANKL, and osteoprotegerin, " Arthritis Research and Therapy, vol. 9, no. 1, article S1, 2007.
157. S. Panizo, A. Cardus, M. Encinas et al. , "RANKL increases vascular smoothmuscle cell calcification through a rank-bmp4-dependent pathway, " Circulation Research, vol. 104, no. 9, pp. 1041-1048, 2009.
158. M. Shargorodsky, M. Boaz, A. Luckish, Z. Matas, D. Gavish, and M. Mashavi, "Osteoprotegerin as an independent marker of subclinical atherosclerosis in osteoporotic postmenopausal women, " Atherosclerosis, vol. 204, no. 2, pp. 608-611, 2009.
159. L. L. Demer and Y. Tintut, "Vascular calcification: pathobiology of a multifaceted disease, " Circulation, vol. 117, no. 22, pp. 2938-2948, 2008.
160. S. Mathew, M. Davies, R. Lund, G. Saab, and K. A. Hruska, "Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease, " European Journal of Clinical Investigation, vol. 36, supplement 2, pp. 43-50, 2006.
161. D. V. Barreto, F. D. C. Barreto, A. B. de Carvalho et al. , "Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study, " The American Journal of Kidney Diseases, vol. 52, no. 6, pp. 1139-1150, 2008.
162. T. Adragao, J. Herberth, M. Monier-Faugere et al. , "Low bone volume-a risk factor for coronary calcifications in hemodialysis patients, "Clinical Journal of theAmerican Society of Nephrology, vol. 4, no. 2, pp. 450-455, 2009.
163. S. Moe, T. Drüeke, J. Cunninghamet al. , "Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: improving Global Outcomes (KDIGO), " Kidney International, vol. 69, no. 11, pp. 1945-1953, 2006.
164. S. L. Silverman, "Sclerostin, " Journal of Osteoporosis, vol. 2010, Article ID 941419, 3 pages, 2010.
165. R. Baron and G. Rawadi, "Targeting theWnt/β-catenin pathway to regulate bone formation in the adult skeleton, " Endocrinology, vol. 148, no. 6, pp. 2635-2643, 2007.
166. W. Wei, D. Zeve, J. M. Suh et al. , "Biphasic and dosagedependent regulation of osteoclastogenesis by β-catenin, " Molecular and Cellular Biology, vol. 31, no. 23, pp. 4706-4719, 2011.
167. L. Viaene, G. J. Behets, K. Claes et al. , "Sclerostin: another bonerelated protein related to all-causemortality in haemodialysis?" Nephrology, Dialysis, Transplantation, vol. 28, pp. 3024-3030, 2013.
168. K. Surendran, S. Schiavi, and K. A. Hruska, "Wnt-dependent β-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis, " Journal of theAmerican Society of Nephrology, vol. 16, no. 8, pp. 2373-2384, 2005.
169. G. Hampson, S. Edwards, S. Conroy, G. M. Blake, I. Fogelman, and M. L. Frost, "Therelationship between inhibitors of theWnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women, " Bone, vol. 56, no. 1, pp. 42-47, 2013.
170. J. J. Pinzone, B. M. Hall, N. K. Thudi et al. , "The role ofDickkopf-1 in bone development, homeostasis, and disease, " Blood, vol. 113, no. 3, pp. 517-525, 2009.
171. K. E. S. Poole, R. L. van Bezooijen, N. Loveridge et al. , "Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation, " FASEB Journal, vol. 19, no. 13, pp. 1842-1844, 2005.
172. D. Cejka, J. Herberth, A. J. Branscum et al. , "Sclerostin and dickkopf-1 in renal osteodystrophy, " Clinical Journal of the American Society of Nephrology, vol. 6, no. 4, pp. 877-882, 2011.
173. F. C. Caira, S. R. Stock, T. G. Gleason et al. , "Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation, " Journal of the American College of Cardiology, vol. 47, no. 8, pp. 1707-1712, 2006.
174. J. Shao, S. Cheng, J. M. Pingsterhaus, N. Charlton-Kachigian, A. P. Loewy, and D. A. Towler, "Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals, " Journal of Clinical Investigation, vol. 115, no. 5, pp. 1210-1220, 2005.
175. D. Zhu, N. C. W. Mackenzie, J. L. Millán, C. Farquharson, and V. E. MacRae, "The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells, " PLoS ONE, vol. 6, no. 5, Article ID e19595, 2011.
176. M. T. Drake, B. Srinivasan, U. I. Mödder et al. , "Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women, " The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 11, pp. 5056-5062, 2010.
177. T. B. Drüeke and M. H. Lafage-Proust, "Sclerostin: justonemore player in renal bone disease?" Clinical Journal of the American Society of Nephrology, vol. 6, no. 4, pp. 700-703, 2011.
178. U. I. Mödder, K. A. Hoey, S. Amin et al. , "Relation of age, gender, and bone mass to circulating sclerostin levels in women and men, " Journal of Bone and Mineral Research, vol. 26, no. 2, pp. 373-379, 2011.
179. M.-S. M. Ardawi, H. A. Al-Kadi, A. A. Rouzi, and M. H. Qari, "Determinants of serum sclerostin in healthy pre-and postmenopausal women, " Journal of Bone and Mineral Research, vol. 26, no. 12, pp. 2812-2822, 2011.
180. A. García-Martín, P. Rozas-Moreno, R. Reyes-García et al. , "Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus, " The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 1, pp. 234-241, 2012.
181. E. Schulz, K. Arfai, X. Liu, J. Sayre, and V. Gilsanz, "Aortic calcification and the risk of osteoporosis and fractures, " The Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 9, pp. 4246-4253, 2004.
182. G. J. Atkins, P. S. Rowe, H. P. Lim et al. , "Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through aMEPE-ASARMdependent mechanism, " Journal of Bone and Mineral Research, vol. 26, no. 7, pp. 1425-1436, 2011.
183. F. Malberti, "Hyperphosphataemia: treatment options, " Drugs, vol. 73, no. 7, pp. 673-688, 2013.
184. R. B. de Oliveira, F. G. Graciolli, L. M. dos Reis et al. , "Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders, " Nephrology, Dialysis, Transplantation, vol. 28, no. 10, pp. 2510-2517, 2013.
185. A. J. Hutchison, C. P. Smith, and P. E. C. Brenchley, "Pharmacology, efficacy and safety of oral phosphate binders, " Nature Reviews Nephrology, vol. 7, no. 10, pp. 578-589, 2011.
186. W. Qunibi, M. Moustafa, L. R. Muenz et al. , "A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patientswith comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study, " American Journal of Kidney Diseases, vol. 51, pp. 952-965, 2008.
187. O. Phan, M. Maillard, C. Peregaux et al. , "PA21, a new ironbased noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats, "TheJournal of Pharmacology and ExperimentalTherapeutics, vol. 346, no. 2, pp. 281-289, 2013.
188. G. E. Striker, "Beyond phosphate binding: the effect of binder therapy on novel biomarkers may have clinical implications for the management of chronic kidney disease patients, " Kidney International, vol. 76, pp. S1-S2, 2009.
189. M. Wolf, A. Shah, O. Gutierrez et al. , "Vitamin D levels and early mortality among incident hemodialysis patients, " Kidney International, vol. 72, no. 8, pp. 1004-1013, 2007.
190. W. L. Lau, E. M. Leaf, M. C. Hu et al. , "Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet, " Kidney International, vol. 82, no. 12, pp. 1261-1270, 2012.
191. M. Teng, M. Wolf, M. N. Ofsthun et al. , "Activated injectable vitamin D and hemodialysis survival: a historical cohort study, " Journal of the American Society of Nephrology, vol. 16, no. 4, pp. 1115-1125, 2005.
192. M. Teng, M. Wolf, E. Lowrie, N. Ofsthun, J. M. Lazarus, and R. Thadhani, "Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy, " The New England Journal of Medicine, vol. 349, no. 5, pp. 446-456, 2003.
193. J. W. Ryan, P. H. Anderson, A. G. Turner, and H. A. Morris, "Vitamin D activities and metabolic bone disease, " Clinica Chimica Acta, vol. 425, pp. 148-152, 2013.
194. P. H. Anderson, N. N. Lam, A. G. Turner et al. , "The pleiotropic effects of vitaminDin bone, "TheJournal of Steroid Biochemistry and Molecular Biology, vol. 136, no. 1, pp. 190-194, 2013.
195. L. Lieben, G. Carmeliet, and R. Masuyama, "Calcemic actions of vitamin D: effects on the intestine, kidney and bone, " Best Practice & Research Clinical Endocrinology & Metabolism, vol. 25, no. 4, pp. 561-572, 2011.
196. C. Bosworth and I. H. De Boer, "Impaired vitamin D metabolism in CKD, " Seminars in Nephrology, vol. 33, no. 2, pp. 158-168, 2013.
197. N. H. Bell, S. Shaw, and R. T. Turner, "Evidence that 1, 25-dihydroxyvitamin D3 inhibits the hepatic production of 25-hydroxyvitaminDinman, "The Journal of Clinical Investigation, vol. 74, no. 4, pp. 1540-1544, 1984.
198. R. Westenfeld, T. Krueger, G. Schlieper et al. , "Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial, " American Journal of Kidney Diseases, vol. 59, no. 2, pp. 186-195, 2012.
199. H. M. Spronk, B. A. Soute, L. J. Schurgers, H. H. Thijssen, J. G. De Mey, and C. Vermeer, "Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats, " Journal of Vascular Research, vol. 40, pp. 531-537, 2003.
200. G. A. Block, K. J. Martin, A. L. M. de Francisco et al. , "Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis, " The New England Journal of Medicine, vol. 350, no. 15, pp. 1516-1525, 2004.
201. S. Jung, U. Querfeld, D. Müller, B. Rudolph, H. Peters, and S. Krämer, "Submaximal suppression of parathyroid hormone ameliorates calcitriol-induced aortic calcification and remodeling and myocardial fibrosis in uremic rats, " Journal of Hypertension, vol. 30, no. 11, pp. 2182-2191, 2012.
202. P. Raggi, G. M. Chertow, P. U. Torres et al. , "The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis, "Nephrology, Dialysis, Transplantation, vol. 26, no. 4, pp. 1327-1339, 2011.
203. S. Ong and I. H. Coulson, "Diagnosis and treatment of calciphylaxis, " Skinmed, vol. 10, no. 3, pp. 166-170, 2012.
204. A. Pasch, T. Schaffner, U. Huynh-Do, B. M. Frey, F. J. Frey, and S. Farese, "Sodiumthiosulfate prevents vascular calcifications in uremic rats, " Kidney International, vol. 74, no. 11, pp. 1444-1453, 2008.
205. S. J. Mathews, L. de Las Fuentes, P. Podaralla et al. , "Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy, " American Journal of Nephrology, vol. 33, no. 2, pp. 131-138, 2011.
206. G. Schlieper, V. Brandenburg, M. Ketteler, and J. Floege, "Sodium thiosulfate in the treatment of calcific uremic arteriolopathy, " Nature Reviews Nephrology, vol. 5, no. 9, pp. 539-543, 2009.
207. K. Nitta, T. Akiba, K. Suzuki et al. , "Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis, " The American Journal of Kidney Diseases, vol. 44, pp. 680-688, 2004.
208. P. Monney, Q. V. Nguyen, H. Perroud, and E. Descombes, "Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure, " Nephrology, Dialysis, Transplantation, vol. 19, pp. 2130-2132, 2004.
209. W. C. Liu, J. F. Yen, C. L. Lang, M. T. Yan, and K. C. Lu, "Bisphophonates in CKD patients with low bone mineral density, " The Scientific World Journal, vol. 2013, Article ID 837573, 11 pages, 2013.
210. N. Shiraishi, K. Kitamura, T. Miyoshi et al. , "Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium, " The American Journal of Kidney Diseases, vol. 48, pp. 151-154, 2006.
211. N. D. Toussaint, K. K. Lau, B. J. Strauss, K. R. Polkinghorne, and P. G. Kerr, "Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial, " American Journal of Kidney Diseases, vol. 56, pp. 57-68, 2010.
212. C. H. Byon, Y. Sun, J. Chen et al. , "Runx2-upregulated receptor activator of nuclear factor kappaB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages, " Arteriosclerosis, Thrombosis and Vascular Biology, vol. 31, pp. 1387-1396, 2011.
213. S. Helas, C. Goettsch, M. Schoppet et al. , "Inhibition of receptor activator of NF-kB ligand by denosumab attenuates vascular calciumdeposition in mice, "TheAmerican Journal of Pathology, vol. 175, no. 2, pp. 473-478, 2009.
214. K. G. Saag, E. Shane, S. Boonen et al. , "Teriparatide or alendronate in glucocorticoid-induced osteoporosis, " The New England Journal of Medicine, vol. 357, pp. 2028-2039, 2007.
215. M. Y. Shin and I. S. Kwun, "Phosphate-induced rat vascular smooth muscle cell calcification and the implication of zinc deficiency in a7r5 cell viability, " Preventive Nutrition and Food Science, vol. 18, no. 2, pp. 92-97, 2013.
216. Y. Hiruma, A. Inoue, S. Hirose, and H. Hagiwara, "Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae, " Biochemical and Biophysical Research Communications, vol. 230, pp. 176-178, 1997.
217. X. X. Guan, Y. Zhou, and J. Y. Li, "Reciprocal roles of angiotensin II and angiotensin II receptors blockade (ARB) in regulating Cbfa1/RANKL via cAMP signaling pathway: possible mechanism for hypertension-related osteoporosis and antagonistic effect of ARB on hypertension-related osteoporosis, " International Journal ofMolecular Sciences, vol. 12, no. 7, pp. 4206-4213, 2011.
218. Z. B. Armstrong, D. R. Boughner, M. Drangova, and K. A. Rogers, "Angiotensin II type 1 receptor blocker inhibits arterial calcification in a pre-clinical model, " Cardiovascular Research, vol. 90, pp. 165-170, 2011.